{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:02:09Z","timestamp":1779904929750,"version":"3.53.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005934","name":"Malm\u00f6 University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005934","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oral lichen planus (OLP) is a chronic immune\u2011mediated inflammatory disorder affecting the oral mucosa and characterized by recurring exacerbations and remissions. Complete healing is uncommon. Currently, there is no established curative therapy for OLP. Management strategies are aimed at alleviating clinical symptoms by reducing the underlying inflammatory response. Although some effect of topical corticosteroids has been reported, the level of evidence remains low, as few studies are randomized and placebo controlled. This study evaluated the efficacy of clobetasol compared with placebo in the treatment of symptomatic OLP and sought to determine whether once-daily is as effective as twice-daily administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with symptomatic OLP were randomly allocated to three treatment groups: clobetasol propionate 0.025% oral gel twice daily (Active 2,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922), clobetasol propionate 0.025% oral gel once daily and placebo oral gel once daily (Active 1,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926) and placebo oral gel twice daily (Placebo,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925). All three groups were instructed to rinse with the assigned oral gel for 1\u00a0min twice daily for 4 weeks. The primary outcome was the Oral Disease Severity Score (ODSS). Secondary outcomes were the visual analogue scale (VAS) score for pain, the VAS score for burning sensation, the Oral Health Impact Profile (OHIP-14), and the Global Rating of Change (GRC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In both intervention groups (Active 2 and 1), improvement in the ODSS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) and the GRC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) after 4 weeks was significant compared with control group (Placebo). No significant differences were observed between the intervention groups in ODSS and GRC. Nor were any significant differences in the pain score, the burning sensation score, or the OHIP-14 noted between the intervention groups and the control group. Adverse events were mild with no significant differences between the intervention groups and the control group. Despite receiving antifungal prophylaxis, 27% of the participants had oral candidiasis at the end of treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results suggest that topical clobetasol propionate 0.025% oral gel is more effective than placebo in improving disease severity (ODSS) and global change (GRC) in patients with symptomatic OLP. The results also suggest that once-daily treatment is as effective as twice-daily treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This trial was registered at Clinical Trials.gov on April 20, 2020, under registration number NCT04364555.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12903-026-08599-7","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:16:29Z","timestamp":1779286589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Topical clobetasol propionate 0.025% oral gel in the treatment of oral lichen planus: a double-blind, randomized placebo-controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Fredrik","family":"Gr\u00e4nse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv","family":"Kroona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Truedsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Larsson Wexell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"G\u00f6trick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"4","key":"8599_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/odi.13323","volume":"27","author":"M Gonz\u00e1lez-Moles","year":"2021","unstructured":"Gonz\u00e1lez-Moles M, Warnakulasuriya S, Gonz\u00e1lez-Ruiz I, Gonz\u00e1lez-Ruiz L, Ay\u00e9n \u00c1, Lenouvel D, et al. Worldwide prevalence of oral lichen planus: A systematic review and meta-analysis. Oral Dis. 2021;27(4):813\u201328.","journal-title":"Oral Dis"},{"issue":"4","key":"8599_CR2","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/odi.14142","volume":"29","author":"A El-Howati","year":"2023","unstructured":"El-Howati A, Thornhill MH, Colley HE, Murdoch C. Immune mechanisms in oral lichen planus. Oral Dis. 2023;29(4):1400\u201315.","journal-title":"Oral Dis"},{"issue":"8","key":"8599_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1600-0714.2008.00662.x","volume":"37","author":"BE McCartan","year":"2008","unstructured":"McCartan BE, Healy CM. The reported prevalence of oral lichen planus: a review and critique. J Oral Pathol Med. 2008;37(8):447\u201353.","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"8599_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.otc.2010.09.004","volume":"44","author":"P Parashar","year":"2011","unstructured":"Parashar P. Oral lichen planus. Otolaryngol Clin North Am. 2011;44(1):89\u2013107. vi.","journal-title":"Otolaryngol Clin North Am"},{"issue":"2","key":"8599_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cden.2014.01.001","volume":"58","author":"SS De Rossi","year":"2014","unstructured":"De Rossi SS, Ciarrocca K. Oral lichen planus and lichenoid mucositis. Dent Clin North Am. 2014;58(2):299\u2013313.","journal-title":"Dent Clin North Am"},{"issue":"1","key":"8599_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0030-4220(68)90194-1","volume":"25","author":"JO Andreasen","year":"1968","unstructured":"Andreasen JO. Oral lichen planus. 1. A clinical evaluation of 115 cases. Oral Surg Oral Med Oral Pathol. 1968;25(1):31\u201342.","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"9","key":"8599_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1034\/j.1600-0714.2003.00125.x","volume":"32","author":"EH van der Meij","year":"2003","unstructured":"van der Meij EH, van der Waal I. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. J Oral Pathol Med. 2003;32(9):507\u201312.","journal-title":"J Oral Pathol Med"},{"issue":"3","key":"8599_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/hed.26006","volume":"42","author":"O Iocca","year":"2020","unstructured":"Iocca O, Sollecito TP, Alawi F, Weinstein GS, Newman JG, De Virgilio A, et al. Potentially malignant disorders of the oral cavity and oral dysplasia: A systematic review and meta-analysis of malignant transformation rate by subtype. Head Neck. 2020;42(3):539\u201355.","journal-title":"Head Neck"},{"issue":"1","key":"8599_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40257-023-00814-3","volume":"25","author":"A Louisy","year":"2024","unstructured":"Louisy A, Humbert E, Samimi M. Oral Lichen Planus: An Update on Diagnosis and Management. Am J Clin Dermatol. 2024;25(1):35\u201353.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"8599_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/09629359891126","volume":"7","author":"A Ahluwalia","year":"1998","unstructured":"Ahluwalia A. Topical glucocorticoids and the skin\u2013mechanisms of action: an update. Mediators Inflamm. 1998;7(3):183\u201393.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"8599_CR11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/jcpe.12385","volume":"42","author":"SJ Stone","year":"2015","unstructured":"Stone SJ, Heasman PA, Staines KS, McCracken GI. The impact of structured plaque control for patients with gingival manifestations of oral lichen planus: a randomized controlled study. J Clin Periodontol. 2015;42(4):356\u201362.","journal-title":"J Clin Periodontol"},{"issue":"2","key":"8599_CR12","first-page":"Cd001168","volume":"2","author":"G Lodi","year":"2020","unstructured":"Lodi G, Manfredi M, Mercadante V, Murphy R, Carrozzo M. Interventions for treating oral lichen planus: corticosteroid therapies. Cochrane Database Syst Rev. 2020;2(2):Cd001168.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"8599_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0030-4220(93)90091-H","volume":"75","author":"AB Vo\u00fbte","year":"1993","unstructured":"Vo\u00fbte AB, Schulten EA, Langendijk PN, Kostense PJ, van der Waal I. Fluocinonide in an adhesive base for treatment of oral lichen planus. A double-blind, placebo-controlled clinical study. Oral Surg Oral Med Oral Pathol. 1993;75(2):181\u20135.","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"5","key":"8599_CR14","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/odi.12653","volume":"23","author":"M Siponen","year":"2017","unstructured":"Siponen M, Huuskonen L, Kallio-Pulkkinen S, Nieminen P, Salo T. Topical tacrolimus, triamcinolone acetonide, and placebo in oral lichen planus: a pilot randomized controlled trial. Oral Dis. 2017;23(5):660\u20138.","journal-title":"Oral Dis"},{"issue":"5","key":"8599_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/odi.12821","volume":"24","author":"PG Arduino","year":"2018","unstructured":"Arduino PG, Campolongo MG, Sciannameo V, Conrotto D, Gambino A, Cabras M, et al. Randomized, placebo-controlled, double-blind trial of clobetasol propionate 0.05% in the treatment of oral lichen planus. Oral Dis. 2018;24(5):772\u20137.","journal-title":"Oral Dis"},{"issue":"3","key":"8599_CR16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/odi.13790","volume":"28","author":"P Yuan","year":"2022","unstructured":"Yuan P, Qiu X, Ye L, Hou F, Liang Y, Jiang H, et al. Efficacy of topical administration for oral lichen planus: A network meta-analysis. Oral Dis. 2022;28(3):670\u201381.","journal-title":"Oral Dis"},{"issue":"10","key":"8599_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1600-0714.1992.tb00974.x","volume":"21","author":"K Thongprasom","year":"1992","unstructured":"Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med. 1992;21(10):456\u20138.","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"8599_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/09546639409081837","volume":"5","author":"PO R\u00f6dstr\u00f6m","year":"1994","unstructured":"R\u00f6dstr\u00f6m PO, Hakeberg M, Jontell M, Nordin P. Erosive oral lichen planus treated with clobetasol propionate and triamcinolone acetonide in Orabase: A double-blind clinical trial. J Dermatological Treat. 1994;5(1):7\u201310.","journal-title":"J Dermatological Treat"},{"issue":"3","key":"8599_CR19","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/odi.14588","volume":"30","author":"MJ Einarsdottir","year":"2024","unstructured":"Einarsdottir MJ, Bankvall M, Robledo-Sierra J, R\u00f6dstr\u00f6m P-O, Bergthorsdottir R, Trimpou P, et al. Topical clobetasol treatment for oral lichen planus can cause adrenal insufficiency. Oral Dis. 2024;30(3):1304\u201312.","journal-title":"Oral Dis"},{"key":"8599_CR20","doi-asserted-by":"publisher","first-page":"1391754","DOI":"10.3389\/fmed.2024.1391754","volume":"11","author":"T Zheng","year":"2024","unstructured":"Zheng T, Liu C, Wang Y, Zhou R, Wu D, Tan J, et al. Efficacy and safety of topical clobetasol propionate in comparison with alternative treatments in oral lichen planus: an updated systematic review and meta-analysis. Front Med (Lausanne). 2024;11:1391754.","journal-title":"Front Med (Lausanne)"},{"issue":"20","key":"8599_CR21","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration","year":"2013","unstructured":"World Medical Association Declaration. of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"key":"8599_CR22","doi-asserted-by":"publisher","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","volume":"389","author":"S Hopewell","year":"2025","unstructured":"Hopewell S, Chan AW, Collins GS, Hr\u00f3bjartsson A, Moher D, Schulz KF, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123.","journal-title":"BMJ"},{"key":"8599_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3109\/00016356309011240","volume":"21","author":"H Loe","year":"1963","unstructured":"Loe H, Silness J. Periodontal disease in pregnancy I. Prevalence and severity. Acta Odontol Scand. 1963;21:533\u201351.","journal-title":"Acta Odontol Scand"},{"issue":"Suppl 1","key":"8599_CR24","first-page":"S173","volume":"89","author":"PN Papapanou","year":"2018","unstructured":"Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, et al. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018;89(Suppl 1):S173\u201382.","journal-title":"J Periodontol"},{"key":"8599_CR25","doi-asserted-by":"crossref","unstructured":"Zhao W, Lin D, Deng S, Wang S, Guo Y, Yang J et al. Synergistic Efficacy of Plaque Control with Intralesional Triamcinolone Acetonide Injection on Erosive Non-Gingival Oral Lichen Planus: A Randomized Controlled Clinical Trial. Int J Environ Res Public Health. 2022;19(21):13787.","DOI":"10.3390\/ijerph192113787"},{"issue":"12","key":"8599_CR26","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1002\/cam4.1221","volume":"6","author":"HY Sroussi","year":"2017","unstructured":"Sroussi HY, Epstein JB, Bensadoun RJ, Saunders DP, Lalla RV, Migliorati CA, et al. Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med. 2017;6(12):2918\u201331.","journal-title":"Cancer Med"},{"issue":"8","key":"8599_CR27","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1111\/odi.14447","volume":"29","author":"SP Unnikrishnan","year":"2023","unstructured":"Unnikrishnan SP, Rampersaud E, McGee A, Cruickshank ME, Abu-Eid R, Hijazi K. Disease severity scoring systems in mucosal lichen planus: A systematic review. Oral Dis. 2023;29(8):3136\u201351.","journal-title":"Oral Dis"},{"issue":"4","key":"8599_CR28","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1365-2133.2007.08106.x","volume":"157","author":"M Escudier","year":"2007","unstructured":"Escudier M, Ahmed N, Shirlaw P, Setterfield J, Tappuni A, Black MM, et al. A scoring system for mucosal disease severity with special reference to oral lichen planus. Br J Dermatol. 2007;157(4):765\u201370.","journal-title":"Br J Dermatol"},{"issue":"6","key":"8599_CR29","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/bjd.20968","volume":"186","author":"M Ormond","year":"2022","unstructured":"Ormond M, McParland H, Thakrar P, Donaldson A, Andiappan M, Cook RJ, et al. Validation of an Oral Disease Severity Score for use in oral lichen planus. Br J Dermatol. 2022;186(6):1045\u20137.","journal-title":"Br J Dermatol"},{"issue":"2","key":"8599_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0304-3959(76)90113-5","volume":"2","author":"J Scott","year":"1976","unstructured":"Scott J, Huskisson EC. Graphic representation of pain. Pain. 1976;2(2):175\u201384.","journal-title":"Pain"},{"issue":"3","key":"8599_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/0194599812473237","volume":"148","author":"YC Lee","year":"2013","unstructured":"Lee YC, Shin SY, Kim SW, Eun YG. Intralesional injection versus mouth rinse of triamcinolone acetonide in oral lichen planus: a randomized controlled study. Otolaryngol Head Neck Surg. 2013;148(3):443\u20139.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"8599_CR32","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1600-0528.1997.tb00941.x","volume":"25","author":"GD Slade","year":"1997","unstructured":"Slade GD. Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol. 1997;25(4):284\u201390.","journal-title":"Community Dent Oral Epidemiol"},{"issue":"3","key":"8599_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1179\/jmt.2009.17.3.163","volume":"17","author":"SJ Kamper","year":"2009","unstructured":"Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther. 2009;17(3):163\u201370.","journal-title":"J Man Manip Ther"},{"issue":"2","key":"8599_CR34","first-page":"91","volume":"31","author":"C H\u00e4gglin","year":"2007","unstructured":"H\u00e4gglin C, Berggren U, Hakeberg M, Edvardsson A, Eriksson M. Evaluation of a Swedish version of the OHIP-14 among patients in general and specialist dental care. Swed Dent J. 2007;31(2):91\u2013101.","journal-title":"Swed Dent J"},{"issue":"2","key":"8599_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1600-0714.2008.00688.x","volume":"38","author":"M Carbone","year":"2009","unstructured":"Carbone M, Arduino PG, Carrozzo M, Caiazzo G, Broccoletti R, Conrotto D, et al. Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations. J Oral Pathol Med. 2009;38(2):227\u201333.","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"8599_CR36","first-page":"22","volume":"13","author":"JQ Del Rosso","year":"2020","unstructured":"Del Rosso JQ. Topical Corticosteroid Therapy for Psoriasis-A Review of Clobetasol Propionate 0.025% Cream and the Clinical Relevance of Penetration Modification. J Clin Aesthet Dermatol. 2020;13(2):22\u20139.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"5","key":"8599_CR37","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s13555-021-00591-z","volume":"11","author":"S Sidgiddi","year":"2021","unstructured":"Sidgiddi S, Naqvi SMH, Shenoy M, Balraj DN, Kothari J, Gupta S, et al. Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study. Dermatol Ther (Heidelb). 2021;11(5):1717\u201332.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"8599_CR38","unstructured":"The Dental and Pharmaceutical Benefits Agency, Clobetasolpropionate Stockholm TLV. 2010. [updated 2010\/10\/04]. Available from: https:\/\/www.tlv.se\/download\/18.467926b615d084471ac3230d\/1510316374341\/bes101004-klobetasolpropionat-apl.pdf. accessed 16\/01\/2026."},{"issue":"3","key":"8599_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/jop.12604","volume":"47","author":"P Wiriyakijja","year":"2018","unstructured":"Wiriyakijja P, Fedele S, Porter SR, Mercadante V, Ni Riordain R. Patient-reported outcome measures in oral lichen planus: A comprehensive review of the literature with focus on psychometric properties and interpretability. J Oral Pathol Med. 2018;47(3):228\u201339.","journal-title":"J Oral Pathol Med"},{"issue":"9","key":"8599_CR40","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/sj.bdj.2017.889","volume":"223","author":"RNR Wiriyakijja","year":"2017","unstructured":"Wiriyakijja RNR. Patient reported outcome and experience measures of oral disease in oral medicine. Br Dent J. 2017;223(9):713.","journal-title":"Br Dent J"},{"issue":"1","key":"8599_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/jop.13270","volume":"51","author":"MT Brennan","year":"2022","unstructured":"Brennan MT, Madsen LS, Saunders DP, Napenas JJ, McCreary C, Ni Riordain R, et al. Efficacy and safety of a novel mucoadhesive clobetasol patch for treatment of erosive oral lichen planus: A phase 2 randomized clinical trial. J Oral Pathol Med. 2022;51(1):86\u201397.","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"8599_CR42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12105-011-0318-3","volume":"6","author":"I Kaplan","year":"2012","unstructured":"Kaplan I, Ventura-Sharabi Y, Gal G, Calderon S, Anavi Y. The dynamics of oral lichen planus: a retrospective clinicopathological study. Head Neck Pathol. 2012;6(2):178\u201383.","journal-title":"Head Neck Pathol"},{"issue":"7398","key":"8599_CR43","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1136\/bmj.326.7398.1083","volume":"326","author":"V Morton","year":"2003","unstructured":"Morton V, Torgerson DJ. Effect of regression to the mean on decision making in health care. BMJ. 2003;326(7398):1083\u20134.","journal-title":"BMJ"},{"key":"8599_CR44","doi-asserted-by":"publisher","first-page":"e1119","DOI":"10.1136\/bmj.e1119","volume":"344","author":"A Hr\u00f3bjartsson","year":"2012","unstructured":"Hr\u00f3bjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ. 2012;344:e1119.","journal-title":"BMJ"},{"issue":"2","key":"8599_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/odi.12399","volume":"22","author":"DR Marable","year":"2016","unstructured":"Marable DR, Bowers LM, Stout TL, Stewart CM, Berg KM, Sankar V, et al. Oral candidiasis following steroid therapy for oral lichen planus. Oral Dis. 2016;22(2):140\u20137.","journal-title":"Oral Dis"},{"key":"8599_CR46","doi-asserted-by":"crossref","unstructured":"Marti\u0107 D, Glavina A, Lugovi\u0107-Mihi\u0107 L, Vilibi\u0107 M. Psychoneurobiological Aspects of Burning Mouth Syndrome and Oral Lichen Planus: A Narrative Review. Med (Kaunas). 2025;61(8):1489.","DOI":"10.3390\/medicina61081489"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-026-08599-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-026-08599-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-026-08599-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:02:16Z","timestamp":1779901336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12903-026-08599-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8599"],"URL":"https:\/\/doi.org\/10.1186\/s12903-026-08599-7","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Informed consent was received from all participants. The study was approved by the Medical Products Agency in Sweden (Daybook no. [Dnr]: 5.1-2020-133) and the Regional Ethics Review Board in Lund, Sweden (Dnr: 2019-06541; Dnr: 2024-03429-02). The study protocol was registered in the European Union Drug Regulating Authorities Clinical Trials (EudraCT) database (EU no.: 2018-004222-28) and at Clinical Trials.gov (NCT04364555).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"910"}}